# OnCo record zolbetuximab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/zolbetuximab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "zolbetuximab" ;
  schema:name "Zolbetuximab"@en ;
  schema:description "Zolbetuximab is the first drug against Claudin 18.2, a protein exposed on stomach cancer cells. Added to chemotherapy it extends survival by two to three months; nausea is the price."@en ;
  schema:url <https://onco.cc/drugs/zolbetuximab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Zolbetuximab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q17107865> ;
  schema:citation <https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-Claudin 18.2)" ;
  schema:alternateName "Vyloy" ;
  onco:approval "Japan 2024: CLDN18.2+ HER2- gastric cancer (first approval, March 2024)", "US 2024: First-line CLDN18.2+ (≥75%), HER2- locally advanced/metastatic gastric or GEJ adenocarcinoma with fluoropyrimidine/platinum chemotherapy", "EU 2024: 1L CLDN18.2+ HER2- gastric/GEJ; 19 Sep 2024" ;
  onco:related <https://onco.cc/biomarkers/cldn18-2-expression/> ;
  onco:cancers <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/gastric-cldn18-2-positive/>, <https://onco.cc/cancers/oesophageal-adenocarcinoma/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/companion-diagnostic/> ;
  onco:targets <https://onco.cc/targets/cldn18-2/> ;
  onco:companies <https://onco.cc/companies/astellas/> ;
  onco:terms <https://onco.cc/terms/adcc/> ;
  onco:trials <https://onco.cc/trials/spotlight-glow/>, <https://onco.cc/trials/nct06901531/>, <https://onco.cc/trials/nct03816163/>, <https://onco.cc/trials/nct03505320/>, <https://onco.cc/trials/nct07431281/> .